Mycophenolic acid exposure in high-and low-weight renal transplant patients after dosing with mycophenolate mofetil in the opticept trial

Therapeutic Drug Monitoring

Volumn 32, Issue 2, 2010, Pages 224-227

  Kaplan, Bruce ^a   Gaston, Robert S ^b   Meier Kriesche, Herwig Ulf ^c   Bloom, Roy D ^d   Shaw, Leslie M ^d  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Mycophenolate mofetil; Mycophenolic acid; Renal transplantation; Tacrolimus; Weight

Indexed keywords

CYCLOSPORIN; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EXPOSURE; FEMALE; HIGH RISK PATIENT; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; DRUG EFFECTS; METABOLISM; MIDDLE AGED; OBESITY; PHYSIOLOGY; PROSPECTIVE STUDY;

ADULT; BODY WEIGHT; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; OVERWEIGHT; PROSPECTIVE STUDIES; THINNESS;

EID: 77950273530     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181d18baa     Document Type: Article

References (22)

1. CellCept [package insert]. Nutley, NJ: Roche; 2009
2. European Mycophenolate Mofetil Co-operative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet. 1995;345: 1321-1325.
3. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation. 1995;60:225-232
4. Tricontinental MMF Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation. 1996; 61:1029-1037.
5. Neylan JF. Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation. 1997;64:1277-1282.
6. van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation. 1999;68: 261-266.
7. Gaston RS, Kaplan B, Shah T, et al. Fixed or controlled-dose myco-phenolate mofetil with standard-or reduced-dose calcineurin inhibitors: the Opticept trial. Am J Transplant. 2009;9:1607-1619.
8. Weber LT, Shipkova M, Armstrong VW, et al. The pharmacokinetic- pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol. 2002;13:759-768.
9. Cattaneo D, Gaspari F, Ferrari S, et al. Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clin Transplant. 2001;15:402-409.
10. Kuypers DR, Claes K, Evenepoel P, et al. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther. 2004;75:434-447.
11. Mourad M, Malaise J, Chaib Eddour D, et al. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clin Chem. 2001;47:1241-1248.
12. Kuypers DR, de Jonge H, Naesens M, et al. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin Ther. 2008;30:673-683.
13. van Gelder T, Shaw LM. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation. 2005;80(Suppl):S244-S253.
14. Yau WP, Vathsala A, Lou HX, et al. Is a standard fixed dose of mycophenolate mofetil ideal for all patients? Nephrol Dial Transplant. 2007;22:3638-3645.
15. Nazemian F, Mohammadpur AH, Abaci B, et al. Pharmacokinetics of mycophenolic acid during the early period after renal transplant. Exp Clin Transplant. 2007;5:658-663.
16. Le Guellec C, Bourgoin H, Büchler M, et al. Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients. Clin Pharmacokinet. 2004;43:253-266.
17. Shum B, Duffull SB, Taylor PJ, et al. Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil. Br J Clin Pharmacol. 2003;56: 188-197.
18. Kuypers DR, Claes K, Evenepoel P, et al. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. J Clin Pharmacol. 2003;43:866-880.
19. Pawinski T, Hale M, Korecka M, et al. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem. 2002; 48:1497-1504.
20. Pöge U, Gerhardt T, Palmedo H, et al. MDRD equations for estimation of GFR in renal transplant recipients. Am J Transplant. 2005;5:1306-1311.
21. Shaw LM, Holt DW, Oellerich M, et al. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit. 2001;23:305-315.
22. Deters M, Kirchner G, Koal T, et al. Influence of cyclosporine on the serum concentration and biliary excretion of mycophenolic acid and 7-O-mycophenolic acid glucuronide. Ther Drug Monit. 2005;27:132-138.